Germany· DE-A57-9d4f0b10b3b8e98a
Wick Sulagil Halsspray
A medicinal product containing lidocaine hydrochloride monohydrate, dequalinium chloride, cetylpyridinium chloride monohydrate, registered in Germany by Wick Pharma Zweigniederlassung Der Procter & Gamble Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Lidocaine Hydrochloride Monohydrate, Dequalinium Chloride, Cetylpyridinium Chloride Monohydrate
- Manufacturer
- Wick Pharma Zweigniederlassung Der Procter & Gamble Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/79339e8a-9053-4716-9a26-3b2935e7279d GET /v1/drugs/79339e8a-9053-4716-9a26-3b2935e7279d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oromucosal Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Lidocaine Hydrochloride Monohydrate, Dequalinium Chloride, Cetylpyridinium Chloride Monohydrate",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about lidocaine hydrochloride monohydrate, dequalinium chloride, cetylpyridinium chloride monohydrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.